Partners Capital Investment Group LLP Makes New Investment in Urogen Pharma $URGN

Key Points

• Partners Capital Investment Group LLP has invested $170,000 in Urogen Pharma by acquiring 15,384 shares during the first quarter.
• Urogen Pharma's stock opened at $19.78 and has a market cap of $915.10 million, while the company reported a negative EPS of ($1.05) for the last quarter, missing estimates.
• Analysts have mixed opinions on Urogen Pharma, with a consensus rating of "Buy" and an average price target of $32.00.

Partners Capital Investment Group LLP bought a new position in shares of Urogen Pharma (NASDAQ:URGN - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 15,384 shares of the company's stock, valued at approximately $170,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of URGN. Geode Capital Management LLC increased its position in Urogen Pharma by 1.4% during the 4th quarter. Geode Capital Management LLC now owns 461,902 shares of the company's stock worth $4,919,000 after purchasing an additional 6,265 shares in the last quarter. Wells Fargo & Company MN increased its position in Urogen Pharma by 2.7% during the 4th quarter. Wells Fargo & Company MN now owns 221,540 shares of the company's stock worth $2,359,000 after purchasing an additional 5,801 shares in the last quarter. Legal & General Group Plc increased its position in Urogen Pharma by 24.6% during the 4th quarter. Legal & General Group Plc now owns 19,845 shares of the company's stock worth $211,000 after purchasing an additional 3,920 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Urogen Pharma during the 4th quarter worth approximately $1,472,000. Finally, Barclays PLC increased its position in Urogen Pharma by 16.0% during the 4th quarter. Barclays PLC now owns 69,325 shares of the company's stock worth $738,000 after purchasing an additional 9,547 shares in the last quarter. Institutional investors and hedge funds own 91.29% of the company's stock.

Insider Buying and Selling at Urogen Pharma

In other Urogen Pharma news, General Counsel Jason Drew Smith sold 7,522 shares of the stock in a transaction on Monday, July 28th. The stock was sold at an average price of $19.14, for a total value of $143,971.08. Following the sale, the general counsel directly owned 41,492 shares of the company's stock, valued at $794,156.88. This trade represents a 15.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Mark Schoenberg sold 10,000 shares of the stock in a transaction on Monday, August 11th. The stock was sold at an average price of $17.69, for a total value of $176,900.00. Following the completion of the sale, the insider directly owned 148,229 shares in the company, valued at $2,622,171.01. This represents a 6.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 27,833 shares of company stock worth $457,467 over the last 90 days. 4.70% of the stock is currently owned by company insiders.

Urogen Pharma Stock Down 4.8%

Shares of Urogen Pharma stock traded down $0.94 on Monday, hitting $18.50. 1,413,546 shares of the company's stock traded hands, compared to its average volume of 1,545,593. The firm's 50-day moving average is $16.50 and its 200 day moving average is $11.94. Urogen Pharma has a 52-week low of $3.42 and a 52-week high of $21.01. The stock has a market cap of $855.88 million, a P/E ratio of -5.57 and a beta of 1.12.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.23). Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%.The firm had revenue of $24.22 million for the quarter, compared to the consensus estimate of $23.06 million. Equities research analysts forecast that Urogen Pharma will post -3.12 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on URGN. Oppenheimer set a $31.00 price objective on shares of Urogen Pharma and gave the company a "buy" rating in a research report on Friday, June 13th. Scotiabank reaffirmed an "outperform" rating on shares of Urogen Pharma in a research report on Friday, June 13th. The Goldman Sachs Group set a $16.00 price objective on shares of Urogen Pharma and gave the company a "neutral" rating in a research report on Friday, June 13th. HC Wainwright lowered their price objective on shares of Urogen Pharma from $50.00 to $40.00 and set a "buy" rating for the company in a research report on Monday, August 11th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $30.00 price objective (up previously from $15.00) on shares of Urogen Pharma in a research report on Friday, June 13th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, Urogen Pharma presently has a consensus rating of "Buy" and an average target price of $32.00.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.